Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06561555
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-10
Brief Title:
A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Pagets Disease
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase II Clinical Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Pagets Disease
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single-center phase II clinical trial Patients with HER2-positive advanced breast and extramammary Pagets disease who met the eligibility criteria were enrolled after signing an informed consent form All patients received treatment with 2mgkg of trastuzumab deruxtecan intravenous infusion every 3 weeks until disease progression Follow-up was conducted until disease progression withdrawal of informed consent by the subject loss to follow-up or death Clinical tumor imaging assessments were performed using RECIST during the treatment process
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None